ABT vs PATH · P/E 25, rev $44.33B vs P/E 19, rev $1.61B
Abbott Laboratories (ABT) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ABT and PATH stock pages for the full models.
Not investment advice.